Labcorp (NYSE: LH) announced the launch of the Marker by Labcorp Genetic Health Panel, a consumer-facing genetic testing product set to become available through its Labcorp OnDemand platform on Aug. 3, 2026.

The panel analyzes 163 genes associated with hereditary cancer, cardiovascular conditions and metabolic conditions linked to more than 100 medically actionable health conditions. The offering includes access to licensed genetic counselors to help consumers interpret results and determine next steps.

Consumers can purchase the panel directly through Labcorp OnDemand and schedule a blood draw at one of the company's more than 2,200 patient service centers nationwide. Results are delivered through Labcorp's secure patient portal and its MyLabcorp mobile app, where consumers can view their genetic health report alongside other available test results.

"Genetic information can play an important role in identifying health risks before symptoms appear, yet millions of people are unaware they carry an inherited genetic variant associated with an increased risk of serious disease," said Dr. Leslie Saltzman, vice president of consumer health solutions at Labcorp.

The panel draws on Labcorp's clinical genetics operations, including its Invitae genetic testing capabilities. According to the company, the new offering allows consumers to access both biomarker and hereditary genetic testing through a single platform.

Labcorp noted that results are not diagnostic and should be considered alongside a person's medical history, family history and other risk factors. Consumers may share results with healthcare providers for further discussion.